Oral administration is still regarded as the most commonly accepted route of drug administration offering numerous advantages including convenience, ease of compliance, and cost-effectiveness. Not surprisingly, desirable oral bioavailability is one of the most important considerations for the successful development of bioactive molecules. Poor oral bioavailability affects drug performance and leads to high intra- and inter-patient variability.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aguiar A.J., Krc J., Kindel A.W., and Samyn J.C., 1967. Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate. J. Pharm. Sci., 56, 847-853.
Amidon G.L., Lennernas H., Shah V.P., and Crison J.R., 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 12(3), 413-420.
Avdeef A., 2001. High throughput measurements of solubility profiles. In Pharmaco-kinetic Optimization in Drug Research; Biological, Physiochemical, and Computa-tional Strategies. Edited by Testa B., et al., Verlag Helvitica Chimica Acta., Zurich, 305-326.
Bevan C. and Lloyd R.S., 2000. A high-throughput screening method for the determination of aqueous drug solubility using laser nepholometry in microtiter plates. Anal. Chem., 72,1781-1787.
Borchardt R.T., Kerns E.H., Hageman M.J., Thakker D.R., and Stevens J.L., 2006. Optimiz-ing the “Drug-Like” Properties of Leads in Drug Discovery. AAPS Press, Arlington, VA.
Connors K.A., Amidon G.L., and Stella V.J., 1986. Chemical Stability of Pharmaceuticals. A Handbook for Pharmacists. 2nd Edition. Wiley, New York.
Curatolo W., 1998. Physicochemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm. Sci. Technol. Today, 1, 387-393.
Dressman J.B., 2000. Dissolution testing of immediate-release products and its application to forcasting in vivo performance. In Oral Drug Absorption, Prediction and Assessment. Edited by Dressman J.B. and Lennernas H., Marcel Dekker, New York, 155-181.
Duddu S., Vakilynejad M., Jamili F., and Grant D., 1993. Stereoselective dissolution of propranolol hydrochloride from hydroxypropyl methylcellulose matrices. Pharm. Res., 10,1648-1653.
Glomme A., M ärz J., and Dressman J.B., 2004. Comparison of a miniaturized shake-flask solubility method with automated potentiometric acid/base titrations and calculated sol-ubilities. J. Pharm. Sci., 94, 1-16.
Gomez-Orellana I., 2005. Strategies to improve oral drug bioavailability. Expert Opin. Drug Deliv., 2(3), 419-433.
Grant D.J.W. and Highuchi T., 1990. Solubility Behavior of Organic Compounds. Wiley, New York.
Gu C.H., Rao D., Gandhi R.B., Hilden J., and Raghavan K., 2005. Using a novel multicompartment dissolution system to predict the effect of gastric pH on the oral absorption of weak bases with poor intrinsic solubility. J. Pharm. Sci., 94, 199-208.
Haleblian J. and McCrone W., 1969. Pharmaceutical applications of polymorphism. J Pharm. Sci., 58, 911-929.
Hancock B.C. and Parks M., 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res., 17(4), 397-404.
Hancock B.C. and Zografi G., 1997. Characteristics and significance of the amorphous stage in pharmaceutical systems. J. Pharm. Sci., 86, 1-12.
Horter D. and Dressman J.B., 1997. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev., 25, 3-14.
Huang L.F. and Tong W.Q., 2004. Impact of solid state properties on developability assess-ment of drug candidates. Adv. Drug Deliv. Rev., 56, 321-334.
Huuskonen J., Salo M., and Taskinen J., 1998. Aqueous solubility prediction of drugs based on molecular topology and neural network modeling. J. Chem. Inf. Comput. Sci., 38, 450-456.
Jain N. and Yalkowsky S.H., 2000. Estimation of the aqueous solubility I: application to organic non-electrolytes. J. Pharm. Sci., 90, 234-252.
Jamali F., 1992. Stereochemistry and bioequivalance. J. Clin. Pharmacol., 32, 930-934.
Johnson K.C. and Swindell A.C., 1996. Guidance in the setting of drug particle size speci-fications to minimize variability in absorption. Pharm. Res., 13, 1795-1798.
Kerns E.H., 2001. High throughput physicochemical profiling for drug discovery. J. Pharm. Sci., 90(11), 1838-1858.
Kerns E.H. and Di L., 2003. Pharmaceutical profiling in drug discovery. Drug Discov. Today, 8(7), 316-323.
Kostewicz E.S., Wunderlich M., Brauns U., Becker R., Bock T., and Dressman J.B., 2004. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J. Pharm. Pharmacol., 56, 43-51.
Leeson P.D. and Davis A.M., 2004. Time-related differences in the physical properties of oral drugs. J. Med. Chem., 47, 6338-6348.
Li S.F., Wong S.M., Sethia S., Almoazen H., Joshi Y., and Serajuddin A.T.M., 2005. Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH. Pharm. Res., 22(4), 628-635.
Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J., 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 23, 3-25.
Lobenberg R., Amidon G.L., and Vieira M., 2000. Solubility as a limiting factor to drug absorption. In Oral Drug Absorption, Prediciton and Assessment. Edited by Dressman J.B and Lennernas H., Marcel Dekker, New York, 137-153.
Macheras P., Reppas C., and Dressman J.B., 1995. Biopharmaceutics of Orally Administered Drugs. Ellis Horwood Limited.
Nystrom C., 1998. Dissolution properties of poorly soluble drugs: theoretical background and possibilities to improve the dissolution behavior. In Emulsions and Nalosuspensions for the Formulation of Poorly Soluble Drugs. Edited by Muller R.H., Benita S., and Bohm B., Medpharm Scientific Publishers, Stuttgart.
Pudipeddi M., Serajuddin A.T.M., Grant D.J.W., and Stahl P.H., 2002. Solubility and dis-solution of weak acids, bases and salts. In Handbook of Pharmaceutical Salts, Properties, Selection, and Use. Edited by Stahl P.H. and Wermuth C.G., Verlag Helvetica Chimica Acta, Zurich, 19-39.
Rabinow B.E., 2004. Nanosuspensions in drug delivery. Nature Rev., 3(9), 785-796.
Ran Y., Jain N., and Yalkowsky S.H., 2001. Prediction of aqueous solubility of organic compounds by the general solubility equition (GSE). J. Chem. Inf. Comput. Sci., 41, 1280-1217.
Shanker R., 2005. Current concepts in the science of solid dispersions. Second Annual Simonelli Conference in Pharmaceutical Sciences. Long Island University.
Taskinen J. and Yliruusi J., 2003. Prediction of physicochemical properties based on neutal network modelling. Adv. Drug Deliv. Rev., 55, 1163-1183.
Tong W.Q., 2000. Preformulation aspects of insoluble compounds. In Water Insoluble Drug Formulation. Edited by Liu R., Interpharm Press, Denver, Colorado, 65-95.
Tong W.Q. and Whitesell G., 1998. In situ salt screening - a useful technique for discovery support and preformulation studies. Pharm. Dev. Tech., 3(2), 215-213.
Vasanthavada M., Tong W.Q., Joshi Y., and Kislalioglu M.S., 2004. Phase behavior of amorphous molecular dispersions I: determination of the degree and mechanism of solid solubility. Pharm. Res., 21(9), 1589-1597.
Vasanthavada M., Tong W.Q., Joshi Y., and Kislalioglu M.S., 2005. Phase behavior of amorphous molecular dispersions II: role of hydrogen bonding in solid solubility and phase separation kinetics. Pharm. Res., 22(3), 440-448.
Veber D.F., Johnson S.R., Cheng H.Y., Smith B.R., Ward K.W., and Kopple K.D., 2002. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem., 45, 2615-2623.
Vieth M., Siegel M.G., Higgs R.E., Watson I.A., Robertson D.H., Savin K.A., Durst G.L., and Hipskind P.A., 2004. Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem., 47, 224-232.
Waterbeemd H., Smith D.A., and Jones B.C., 2001. Lipophilicity in PK design: methyl, ethyl, futile. J. Comput. Aided Mol. Des., 15(3), 273-286.
Wenlock M.C., Austin R.P., Barton P., Davis A.M., and Lesson P., 2003. A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem., 46, 1250-1256.
Winnike R., 2005. Solubility assessment in pharmaceutical development, practical con-siderations for solubility profiling and solubilization techniques. AAPS Short Course on Fundamentals of Preformulation in Pharmaceutical Product Development. Nashville, TN, Nov. 5, 2005.
Yalkowsky S.H., 1999. Solubility and Solubilization in Aqueous Media. American Chemi-cal Society, Washington D.C.
Yalkowsky S.H. and Valvani S.C., 1980. Solubility and partitioning I: solubility of nonelectrolytes in water. J. Pharm. Sci., 69, 912-922.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Tong, WQ.(. (2008). Molecular and Physicochemical Properties Impacting OralAbsorptionofDrugs. In: Krishna, R., Yu, L. (eds) Biopharmaceutics Applications in Drug Development. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-72379-2_2
Download citation
DOI: https://doi.org/10.1007/978-0-387-72379-2_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-72378-5
Online ISBN: 978-0-387-72379-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)